Key points from article :
Insitro has partnered with Genomics England to enhance database searches using advanced machine learning. The collaboration will integrate Insitro’s AI-powered search tools into Genomics England’s database, allowing researchers to find histopathology images, biopsies, and genomic cases based on semantic similarity rather than just visual resemblance. This multimodal approach aims to improve how clinical data is explored and utilized.
The technology will be available to all Genomics England research partners within the biobank’s secure research environment. Insitro’s CEO, Daphne Koller, highlighted that AI can unlock new insights beyond traditional predictive tasks, potentially leading to new medical discoveries and treatments. Genomics England’s Chief Commercial Officer, Parker Moss, called the partnership a crucial step in maximizing research potential and advancing genomic healthcare.
This collaboration builds on Insitro’s growing presence in AI-driven drug discovery. The company has previously partnered with Bristol Myers Squibb to develop treatments for neurodegenerative diseases and acquired Haystack Sciences to further its machine learning capabilities. Last year, Insitro secured $400 million in funding, reinforcing its position as a leader in AI-driven biotechnology.
